Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Cash from Investing Activities data on record, last reported at $74.9 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 119.06% year-over-year to $74.9 million; the TTM value through Dec 2025 reached $118.1 million, up 121.29%, while the annual FY2025 figure was $118.1 million, 121.29% up from the prior year.
  • Cash from Investing Activities reached $74.9 million in Q4 2025 per RVMD's latest filing, up from $24.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $107.9 million in Q2 2024 and bottomed at -$392.9 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is -$47.3 million, with a median of -$2.4 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: soared 1806.67% in 2022, then tumbled 6305.36% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $8.5 million in 2021, then crashed by 183.25% to -$7.1 million in 2022, then crashed by 5254.76% to -$380.4 million in 2023, then dropped by 3.29% to -$392.9 million in 2024, then surged by 119.06% to $74.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $74.9 million in Q4 2025, $24.8 million in Q3 2025, and $34.3 million in Q2 2025.